Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

NCT05184842 is registered in ClinicalTrials.gov with Montefiore Medical Center as lead sponsor.

NCT NCT05184842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05184842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Lead sponsor
Montefiore Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
March 23, 2022
Completion date
March 31, 2027
Enrollment
91 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndromes